Skip to Content
UW Health SMPH
Brad S. Kahl, MD close
Brad S. Kahl, MD
 

Learn More

Break-out Treatment for Lymphoma to be Discussed at Madison Conference

Find a Doctor Quick Search

Find a Doctor Home

For Patients

Need help selecting a doctor?
Call the Welcome Center at
(608) 821-4819 for personal assistance.

For Referring Physicians

How to refer a patient

Brad S. Kahl, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Kahl is an Associate Professor of Medicine at the University of Wisconsin. He is the Director of the UW Lymphoma Service and Clinical Research Director for Hematologic Malignancies for the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center. He received his medical degree from Tufts University where he was elected AOA. He completed all post-graduate training at the University of Wisconsin. Dr. Kahl is certified by the American Board of Internal Medicine in both Internal Medicine and Hematology. His clinical interests involve the care of patients with Hodgkin lymphoma, non-Hodgkin's lymphoma and chronic lymphocytic leukemia. He is a member of several professional organizations including the American Society of Hematology, the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group.

Specialties

Hematology

UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)

Languages Spoken

English
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Internal Medicine
Hematology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School Tufts University School of Medicine, Boston, MA

Awards/Honors

Madison Magazine Top Docs 2012

Best Doctors® in America 2011

Procedures

Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.

Research

Dr. Kahl's research focuses on the development of novel treatments for lymphoma patients, with emphasis on the development of targeted therapies. He is the principal investigator of multiple clinical trials at the University of Wisconsin. He serves on the Eastern Cooperative Oncology Group Lymphoma Core Committee and is the principal investigator of ECOG study 4402, Rituximab Extended Schedule or Retreatment Trial (RESORT).

PubMed Articles
Kenkre VP Kahl BS . What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma? Cancer J. 2012 Sep-Oct;18(5):383-9
[PubMed ID: 23006941]
Kenkre VP Kahl BS . The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways. Curr Hematol Malig Rep. 2012 Sep;7(3):216-20
[PubMed ID: 22688757]
Chang JE Kahl BS . Bendamustine for treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother. 2012 Jul;13(10):1495-505
[PubMed ID: 22663160]
Chang JE Kahl BS . Bendamustine: more ammunition in the battle against mantle cell lymphoma. Leuk Lymphoma. 2012 Jul;53(7):1249-50
[PubMed ID: 22220986]
Young EW Pak C Kahl BS Yang DT Callander NS Miyamoto S Beebe DJ . Microscale functional cytomics for studying hematologic cancers. Blood. 2012 Mar 8;119(10):e76-85
[PubMed ID: 22262772]
Kahl B . Is there a role for "watch and wait" in follicular lymphoma in the rituximab era? Hematology Am Soc Hematol Educ Program. 2012;2012:433-8
[PubMed ID: 23233615]
Kenkre VP Kahl B . Nodal marginal zone lymphoma: what do we really know? Oncology (Williston Park). 2012 Jan;26(1):108-9
[PubMed ID: 22393804]
Chang JE Kahl BS . Current status of targeted therapies for mantle cell lymphoma. Drugs. 2011 Dec 3;71(17):2307-26
[PubMed ID: 22085387]
Chang JE Peterson C Choi S Eickhoff JC Kim K Yang DT Gilbert LA Rogers ES Werndli JE Huie MS McFarland TA Volk M Blank J Callander NS Longo WL Kahl BS . VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol. 2011 Oct;155(2):190-7
[PubMed ID: 21848883]
Kenkre VP Long WL Eickhoff JC Blank JH McFarland TA Bottner W Rezazedeh H Werndli JE Bailey HH Kahl BS . Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011 Sep;52(9):1675-80
[PubMed ID: 21864042]
Kenkre VP Long WL Eickhoff JC Blank JH McFarland TA Bottner W Rezazedeh H Werndli JE Bailey HH Kahl BS . Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma. 2011 May 17;
[PubMed ID: 21585283]
Abouraya M Sacco JC Kahl BS Trepanier LA . Evaluation of sulfonamide detoxification pathways in haematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis. Br J Clin Pharmacol. 2011 Apr;71(4):566-74
[PubMed ID: 21204907]
Yang DT Quann PJ Petrich AM Leith CP Young KH Kahl BS . Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma. Appl Immunohistochem Mol Morphol. 2011 Jan;19(1):62-9
[PubMed ID: 20881841]
Chang JE Seo S Kim KM Werndli JE Bottner WA Rodrigues GA Sanchez FA Saphner TJ Longo WL Kahl BS . Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):379-84
[PubMed ID: 21030351]
Kenkre VP Kahl BS . Follicular lymphoma: emerging therapeutic strategies. Expert Rev Hematol. 2010 Aug;3(4):485-95
[PubMed ID: 21083037]
Kahl BS Cheson BD Friedberg JW . Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clin Adv Hematol Oncol. 2010 May;8(5):1-16
[PubMed ID: 20712081]
Kahl BS Bartlett NL Leonard JP Chen L Ganjoo K Williams ME Czuczman MS Robinson KS Joyce R van der Jagt RH Cheson BD . Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010 Jan 1;116(1):106-14
[PubMed ID: 19890959]
Kahl BS . Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents. Curr Hematol Malig Rep. 2009 Oct;4(4):213-7
[PubMed ID: 20425410]
Chang JE Medlin SC Kahl BS Longo WL Williams EC Lionberger J Kim K Kim J Esterberg E Juckett MB . Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma. 2008 Dec;49(12):2298-307
[PubMed ID: 19052977]
Young KH Leroy K Møller MB Colleoni GW Sánchez-Beato M Kerbauy FR Haioun C Eickhoff JC Young AH Gaulard P Piris MA Oberley TD Rehrauer WM Kahl BS Malter JS Campo E Delabie J Gascoyne RD Rosenwald A Rimsza L Huang J Braziel RM Jaffe ES Wilson WH Staudt LM Vose JM Chan WC Weisenburger DD Greiner TC . Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008 Oct 15;112(8):3088-98
[PubMed ID: 18559976]
Markovina S Callander NS O'Connor SL Kim J Werndli JE Raschko M Leith CP Kahl BS Kim K Miyamoto S . Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008 Aug;6(8):1356-64
[PubMed ID: 18708367]